AustralianSuper Pty Ltd Boosts Stock Position in Pfizer Inc. $PFE

AustralianSuper Pty Ltd boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 72.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,978,774 shares of the biopharmaceutical company’s stock after acquiring an additional 1,675,415 shares during the quarter. AustralianSuper Pty Ltd owned 0.07% of Pfizer worth $101,379,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Brighton Jones LLC increased its position in shares of Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after acquiring an additional 618,117 shares during the period. Revolve Wealth Partners LLC increased its holdings in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 2,087 shares during the period. GC Wealth Management RIA LLC increased its holdings in Pfizer by 46.4% during the 2nd quarter. GC Wealth Management RIA LLC now owns 24,012 shares of the biopharmaceutical company’s stock worth $582,000 after purchasing an additional 7,611 shares during the period. HB Wealth Management LLC raised its position in Pfizer by 16.9% in the 2nd quarter. HB Wealth Management LLC now owns 291,528 shares of the biopharmaceutical company’s stock valued at $7,067,000 after purchasing an additional 42,200 shares in the last quarter. Finally, Trivium Point Advisory LLC boosted its stake in shares of Pfizer by 18.0% in the 2nd quarter. Trivium Point Advisory LLC now owns 36,973 shares of the biopharmaceutical company’s stock valued at $896,000 after buying an additional 5,639 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently weighed in on PFE. HSBC restated a “buy” rating and set a $29.00 target price on shares of Pfizer in a research note on Wednesday, December 10th. Morgan Stanley reduced their price objective on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a report on Friday, December 12th. Zacks Research downgraded shares of Pfizer from a “hold” rating to a “strong sell” rating in a research note on Monday. Sanford C. Bernstein reissued a “market perform” rating and issued a $30.00 target price on shares of Pfizer in a report on Friday, October 31st. Finally, Bank of America cut their price target on Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and an average price target of $28.06.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Cantor Fitzgerald raised its price target on PFE (supportive near-term catalyst that helped shares earlier in the week). Why Is Pfizer Stock Rising Tuesday?
• Positive Sentiment: Some bullish analysts/investors remain confident in Pfizer’s longer-term outlook, arguing recent policy moves don’t change their favorable stance. Pfizer: The Great Healthcare Plan Does Not Change My Bullish Stance
• Neutral Sentiment: Profile pieces and analyst roundups (CEO interview, market commentary) provide context but limited immediate price impact. Pfizer’s CEO on leading after a moonshot—and making deals with Trump
• Neutral Sentiment: Market write-ups note recent outperformance vs. the market on specific days, useful for sentiment tracking but not a structural change. Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
• Negative Sentiment: Zacks Research downgraded Pfizer from “hold” to “strong sell,” which can trigger selling pressure from momentum/quant strategies and affect sentiment. Zacks Downgrade Coverage
• Negative Sentiment: The U.S. Centers for Medicare & Medicaid Services named Pfizer drugs for the next round of Medicare price negotiations — a material policy risk that could pressure revenue for listed products if negotiated prices are reduced. US Medicare names drugs for next price talks
• Negative Sentiment: Earnings preview commentary warns Q4 results may decline versus expectations, raising the risk of a miss or muted guidance that could weigh on the stock. Earnings Preview: Q4 Earnings Expected to Decline
• Negative Sentiment: Competitive risk: early data from Aclaris shows a hair‑loss candidate outperforming Pfizer’s Litfulo in preclinical/early results, a potential headwind for that franchise. Aclaris hair-loss drug shows faster results
• Negative Sentiment: Broader concerns about leverage and underperformance versus peers (Merck, J&J) keep analysts cautious ahead of secular headwinds like waning COVID product demand and an upcoming patent cliff. Pfizer vs. Merck Stock And JNJ

Pfizer Stock Down 2.3%

Pfizer stock opened at $25.89 on Thursday. The company has a market capitalization of $147.17 billion, a P/E ratio of 15.05 and a beta of 0.47. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.69. The stock has a 50-day simple moving average of $25.45 and a 200-day simple moving average of $25.01.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.6%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is 100.00%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.